How Will the Market React to Vericel Corp (VCEL) Stock Getting a Bullish Rating

Overall market sentiment has been high on Vericel Corp (VCEL) stock lately. VCEL receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Vericel Corp has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on VCEL!

See Full VCEL Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With VCEL Stock Today?

Vericel Corp (VCEL) stock has fallen -2.03% while the S&P 500 is higher by 0.34% as of 11:43 AM on Tuesday, Nov 28. VCEL has fallen -$0.73 from the previous closing price of $36.00 on volume of 53,285 shares. Over the past year the S&P 500 has gained 15.18% while VCEL is higher by 67.24%. VCEL lost -$0.22 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Vericel Corp click here.

More About Vericel Corp

Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases. Click Here to get the full Stock Report for Vericel Corp stock.